Financial Performance & Growth - Global medical cannabis net revenue reached $64.8 million in Q1, a 37% increase compared to the prior year period[17] - Aurora achieved positive free cash flow of $9.2 million in Q1 FY26, representing 42% year-over-year growth[111] - The company achieved positive adjusted EBITDA of $10.8 million in Q1 FY26, a 209% increase year-over-year[111] - Bevo contributed record revenues of approximately $23.9 million in Q1, up 4% compared to the prior year period[99] Market Leadership & Expansion - International medical revenue increased 85% in Q1 FY 2026 compared to the prior year period[9] - Aurora is the 1 Canadian Medical share by revenue, with net revenue increasing by 2% compared to the prior year period[9] - Aurora Europe was the 2 supplier of medical cannabis to each core market of Germany and Poland in Q1 FY26[35] - MedReleaf Australia, an Aurora subsidiary, holds approximately 16% market share by revenue and pharmacy dispensed volumes in Australia[57] Product Innovation & Strategy - Innovations in genetics result in all-in per unit costs that are at least 30% better than legacy cultivars[12] - Farm Gas became the 1 selling cultivar in Poland shortly after its launch, with THC levels around 27%[22, 36]

AURORA CANNABIS INC. Interim Condensed Consolidated Financial Statements (Unaudited) For the three months ended June 30, 2025 and 2024 (in Canadian Dollars) AURORA CANNABIS INC. Interim Condensed Consolidated Statements of Financial Position (Unaudited) | ($ thousands) | Note | June 30, 2025 | March 31, 2025 | | --- | --- | --- | --- | | | | $ | $ | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | | 140,160 | 137,921 | | Restricted cash | 9, 2(c) | 45,873 | 47,407 | | Accounts receiva ...

Core Insights - Aurora Cannabis Inc. reported a strong first quarter for fiscal 2026, with a 37% increase in global medical cannabis net revenue, driven by significant growth in international markets, particularly Germany and Poland [2][5][7] - The company achieved over 200% growth in adjusted EBITDA and a 42% increase in positive free cash flow, indicating robust operational performance [2][8][16] - The international medical cannabis segment now represents 57% of total net revenue, highlighting the company's competitive advantage in this high-margin area [3][7] Financial Performance - Total net revenue for Q1 2026 was $98.0 million, up 17% from $83.4 million in the prior year, primarily due to the growth in medical cannabis and plant propagation businesses [5][21] - Adjusted gross margin before fair value adjustments improved to 52% in Q1 2026 from 42% in the prior year, with adjusted gross profit increasing by 42% to $49.0 million [6][21] - Medical cannabis net revenue reached $64.8 million, a 37% increase year-over-year, contributing 66% of total consolidated net revenue [7][21] Segment Performance - International medical cannabis revenue surged by 85% to $37.1 million, driven by increased sales in Australia, Germany, Poland, and the UK [8][21] - Consumer cannabis net revenue decreased by 32% to $7.9 million, as the company prioritized high-margin medical cannabis products over lower-margin consumer offerings [10][21] - Plant propagation revenue from Bevo Farms increased by 4% to $23.9 million, supported by organic growth and expanded product offerings [12][21] Operational Efficiency - Adjusted SG&A expenses rose to $37.4 million, reflecting higher logistics costs associated with European sales and the acquisition of MedReleaf Australia [14][21] - The company maintained a strong balance sheet with approximately $186.0 million in cash and a debt-free cannabis business, with only non-recourse debt of $59.8 million related to Bevo Farms [4][21] Future Outlook - For Q2 2026, the company anticipates continued revenue growth, primarily driven by an 8% to 12% increase in the global medical cannabis segment [17][21] - Consolidated adjusted gross margins are expected to improve, with positive adjusted EBITDA projected to continue [18][21] - Free cash flow is expected to remain positive on an annual basis, despite anticipated cash outflows in Q2 2026 [19][21]

Core Insights - Aurora Cannabis (ACB) is set to release its first-quarter fiscal 2026 results on August 6, with earnings estimated at 18 cents per share and revenues at $70.88 million, indicating a year-over-year earnings growth of 263.6% and a revenue increase of 5.4% [1][2] Financial Performance - The consensus for fiscal 2026 revenues is $272.1 million, reflecting a 7.6% year-over-year rise, while the EPS estimate is 56 cents, suggesting a 100% improvement year-over-year [2] - ACB has surpassed the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 50.10% [2] Market Dynamics - ACB's medical cannabis sales are expected to have increased in Germany and Australia, driven by new product launches, although regulatory disruptions in Poland and seasonal fluctuations may have impacted revenue growth [5][8] - The company has expanded its IndiMed portfolio in Australia, launching TEMPO 22 cultivars to meet rising patient demand, which is likely to enhance top-line growth [7] Operational Developments - ACB's recent $3 million upgrade to its Alpine facility in British Columbia has doubled yields and potency, potentially supporting top-line growth [10] - Despite a projected slight decline in first-quarter revenues compared to the previous quarter, margins are expected to remain robust due to a favorable product mix and cost discipline [11] Valuation and Stock Performance - Year-to-date, ACB shares have gained 5.4%, outperforming peers like Tilray Brands and Canopy Growth [12] - ACB trades at a forward 12-month P/S of 0.9, reflecting stronger growth expectations compared to Tilray Brands (0.65) and a lower valuation than Canopy Growth (1.07) [13]

Core Viewpoint - Aurora Cannabis Inc. is holding its annual general and special meeting on August 8, 2025, and shareholders are encouraged to vote in advance of the proxy voting deadline on August 6, 2025 [1][2][3] Company Information - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company offers a diverse portfolio of brands, including adult-use brands such as Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands like MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co [4] - Aurora also has a controlling interest in Bevo Farms Ltd., which is North America's leading supplier of propagated agricultural plants [4] - The company's common shares are traded on NASDAQ and TSX under the symbol "ACB" [5] Voting Information - Shareholders are advised to vote their shares online or by telephone, following the instructions on their proxy forms [3][4] - For assistance with voting, shareholders can contact Laurel Hill Advisory Group, the company's proxy solicitation agent [4][7]

Financial Performance - Profit before tax (PBT) reached approximately VND 10.7 trillion in 1H25, a 2% year-over-year increase[93] - The Return on Equity (ROE) stood at approximately 20.6%, positioning ACB among the top-performing banks[27, 93] - Net Interest Income (NII) for 1H25 was VND 13043 billion, a 6% decrease year-over-year[33] - Non-Interest Income (NFI) grew by 39% year-over-year, reaching VND 4164 billion in 1H25, driven by investment and FX activities[39] Asset Quality and Growth - Credit growth was 9.1% year-to-date, with total lending reaching approximately VND 634 trillion[10, 93] - Deposit growth was 5.6% year-to-date, with total deposits reaching approximately VND 567 trillion[16, 93] - The Non-Performing Loan (NPL) ratio decreased to 1.27%[47] - The CASA ratio increased to 22.5% in Q2[20] Strategic Initiatives - The investment portfolio accounted for 16% of total assets[23] - Operating costs were effectively managed, maintaining the Cost-to-Income Ratio (CIR) at 32%[42, 43] - The bank launched a VND 2000 billion green/social credit package[90] Outlook - The company projects credit growth of +16%-18% vs 2024[95]

Core Viewpoint - Aurora Cannabis Inc. is set to announce its financial results for the first quarter of 2026 on August 6, 2025, and will host a conference call to discuss these results [1][5]. Group 1: Conference Call Details - The conference call is scheduled for August 6, 2025, at 8:00 a.m. Eastern Time and 6:00 a.m. Mountain Time [2]. - Miguel Martin, Executive Chairman and CEO, along with Simona King, CFO, will lead the conference call and Q&A session [2]. Group 2: Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3]. - The company offers a diverse portfolio of brands, including adult-use brands like Drift and San Rafael '71, and medical brands such as MedReleaf and CanniMed [3]. - Aurora holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3]. Group 3: Stock Information - Aurora's common shares are traded on NASDAQ and TSX under the symbol "ACB" [4].

Industry Overview - The current moment presents a significant opportunity for marijuana stock investors, as legal cannabis remains a volatile sector with multi-state operators (MSOs) and ancillary companies leading the market [1][2] - Despite a decline in the sector's overall value, certain companies continue to achieve gains, indicating ongoing progress within the industry [1] Investment Potential - Long-term investing in cannabis stocks is seen as a speculative opportunity, with the potential for better reform and market conditions over time [2] - Historical trends suggest that positive news regarding cannabis reform has previously led to improved trading conditions for investors [2] Canadian Marijuana Stocks - Canadian marijuana stocks are highlighted as potential investments, particularly during a period when the majority of the sector is undervalued [3] - Investors are encouraged to conduct thorough research and develop a strategic plan to capitalize on potential recoveries in the market [3] Company Highlights - **SNDL Inc.**: Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada, with Q2 2025 earnings set to be reported on July 31 [4][6] - **Aurora Cannabis Inc.**: Involved in the production and sale of cannabis products, recently announced a charitable initiative donating 5% of net profits from specific products to veteran organizations, with a cap of C$200,000 [9][10] - **Village Farms International, Inc.**: Known for its innovative packaging approach through its subsidiary Pure Sunfarms, which aims to enhance consumer experience in cannabis shopping [11][12]

Insights gained from veterans participating in the program help guide the company in crafting custom cannabis strains, focusing on attributes such as aroma, appearance, and effects that matter most to veteran patients. Since its launch in 2022, there have been five purpose-grown strains developed within the Strains for Heroes lineup, and named by veterans, including, Valour, Courage, Honour, Esprit De Corps and United Victory. Aurora is proud to support a growing number of veteran-focused organizations, by ...

Industry Overview - The cannabis industry is currently facing challenges in the public sector, with a lack of momentum and upward trading, but the retail consumer side is performing well, indicating potential for future growth [1][2] - There is optimism among investors regarding federal reform and regulatory improvements, which could reignite interest in the sector [2] Investment Strategy - Investors are adopting a long-term buy-and-hold strategy, focusing on ancillary companies that are not solely dependent on cannabis for revenue, suggesting a shift towards patience and strategic planning [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally, with recent expansion into the Swiss market through its PEACE NATURALS® brand [4] - **Aurora Cannabis Inc.**: Recently achieved EU-GMP Certification for its distribution center, enhancing its commitment to regulatory excellence and operational quality assurance [7] - **Canopy Growth Corporation**: Announced a strategic partnership with Commure to enhance healthcare staff safety, indicating a focus on healthcare-related applications of cannabis [9]